The U.S. Food and Drug Administration has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G) to reduce proteinuria.
Fabhalta is an oral capsule, taken twice daily. Recommended dosing is available in the prescribing information.
FDA first approved Fabhalta in 2023 for the treatment of adults with paroxysmal nocturnal hemoglobinuria. It is also approved under accelerated approval for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression…
